Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK, March 20, 2025 ...

We recently compiled a list of the Top 8 Trending AI Stock Updates On Wall Street Today. In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands ...

The study was based on data ... out next-generation decentralized trials and real-world evidence trials thanks to a series of recent acquisitions. In 2019, Icon acquired Symphony Clinical Research ...

“Our data presentations ... 2 and Phase 3 clinical trials with a strategic focus on two pan-tumor priority programs: investigational mRNA cancer immunotherapies and the next-generation ...

BNT327 is an investigational next-generation bispecific antibody ... BioNTech will present data from the Phase 1 clinical trial LuCa-MERIT-1 (NCT05142189) for its mRNA cancer immunotherapy ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) will present data ... clinical trials with a strategic focus on two pan-tumor priority programs: ...